[{"indications": "Indications\u00a0hypertension (see also notes above); prevention of cardiovascular\r\nevents in patients with established atherosclerotic cardiovascular\r\ndisease, or type 2 diabetes mellitus with target-organ damage", "name": "TELMISARTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain; influenza-like symptoms including pharyngitis and sinusitis;\r\nurinary-tract infection; arthralgia, myalgia, back pain, leg cramps;\r\neczema; less commonly dry mouth, flatulence, anxiety,\r\nvertigo, tendinitis-like symptoms, abnormal vision, increased sweating; rarely bradycardia, tachycardia, dyspnoea, insomnia, depression,\r\nblood disorders, increase in uric acid, eosinophilia, rash, and pruritus;\r\nsyncope and asthenia also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/81217.htm", "doses": ["Hypertension, usually 40\u00a0mg once daily (but 20\u00a0mg may\r\nbe sufficient), increased if necessary after at least 4 weeks, to\r\nmax. 80\u00a0mg once daily", "Prevention of cardiovascular events, 80\u00a0mg once daily"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension (see also notes above); prevention of cardiovascular\r\nevents in patients with established atherosclerotic cardiovascular\r\ndisease, or type 2 diabetes mellitus with target-organ damage", "name": "TELMISARTAN With diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "TELMISARTAN", "With diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain; influenza-like symptoms including pharyngitis and sinusitis;\r\nurinary-tract infection; arthralgia, myalgia, back pain, leg cramps;\r\neczema; less commonly dry mouth, flatulence, anxiety,\r\nvertigo, tendinitis-like symptoms, abnormal vision, increased sweating; rarely bradycardia, tachycardia, dyspnoea, insomnia, depression,\r\nblood disorders, increase in uric acid, eosinophilia, rash, and pruritus;\r\nsyncope and asthenia also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119722.htm", "doses": ["Hypertension, usually 40\u00a0mg once daily (but 20\u00a0mg may\r\nbe sufficient), increased if necessary after at least 4 weeks, to\r\nmax. 80\u00a0mg once daily", "Prevention of cardiovascular events, 80\u00a0mg once daily", "Name[Micardis Plus\u00ae  (Boehringer Ingelheim) ] Tablets 40/12.5, red/white, telmisartan 40\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price\r\n28-tab pack = \u00a312.50\nTablets 80/12.5, red/white, telmisartan 80\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price\r\n28-tab pack = \u00a317.00\nTablets 80/25, yellow/white, telmisartan\r\n80\u00a0mg, hydrochlorothiazide 25\u00a0mg, net price 28-tab pack = \u00a317.00"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}]